3
Participants
Start Date
August 6, 2018
Primary Completion Date
May 14, 2020
Study Completion Date
May 14, 2020
New FVIII products
Kovaltry or Jivi prescribed by the treating Physician
Weill Cornell Medicine, New York
Mary M. Gooley Hemophilia Center, Inc., Rochester
Hemophilia Center of Western Pennsylvania, Pittsburgh
Penn Comprehensive Hemophilia and Thrombophilia Program / Hospital UPENN, Philadelphia
Children's National Medical Center, Washington D.C.
The Johns Hopkins University Hemophilia Treatment Center, Baltimore
Emory / Children's Healthcare of Atlanta, Atlanta
St. Josephs Hemophilia Treatment Center, Tampa
Johns Hopkins All Children's Hospital, St. Petersburg
St. Jude Children's Research Hospital, Memphis
Indiana Hemophilia and Thrombosis Center IHTC, Indianapolis
Univ of Michigan Hemophilia and Coagulation Disorders, Ann Arbor
Michigan State University Center for Bleeding Disorders & Clotting Disorders, East Lansing
Blood Center of Wisconsin, Inc. /Childrens Hosp of Wisconsin, Milwaukee
Bleeding and Clotting Disorders Institute, Peoria
Children's Mercy Hospital (Kansas City), Kansas City
Louisiana Center for Bleeding and Clotting Disorders / Tulane, New Orleans
UT Southwestern/Children's Health Dallas, Dallas
University of Colorado Denver Hemophilia and Thrombosis Center, Aurora
University of California, San Diego, La Jolla
Oregon Health & Science University, Portland
BloodWorks (Puget Sound), Seattle
Yale Hemophilia Treatment Center, New Haven
Maine Hemophilia and Thrombosis Center, Scarborough
Boston Hemophilia Center at Children's Hospital of Boston/Brigham Women's, Boston
Dartmouth-Hitchcock Comprehensive Hemophilia and Thrombosis Center, Lebanon
Children's Hospital of Philadelphia (CHOP), Philadelphia
Lead Sponsor
American Thrombosis and Hemostasis Network
NETWORK
Bayer
INDUSTRY